LONDON, UNITED KINGDOM , April 19, 2018 (GLOBE NEWSWIRE) -- Plandai Biotechnology Inc. (OTC Markets: PLPL) (the “Company” or “Plandai”), a producer of nutraceutical and highly phyto-available extracts, is pleased to provide an update on its cannabis business strategy and opportunities.
Using the Company’s proprietary processing technology, Plandaí intends to establish that it can produce a full-profile cannabis extract, Phytofare® Cannabis Complex, that contains both CBD and the precursor acid form of THC found in live cannabis plant. Based on prior, successfully, published USD/Plandai bioavailability studies with oil based fruits, Plandaí’s hypothesis is that the resultant extract will have the superior bioavailability of other Phytofare® extracts with the added benefit of being non-psychoactive.
Callum Cottrell-Duffield, Chief Operating Officer of Plandaí, commented, “We get asked all the time—what is it about Phytofare® that makes it so much better than generic extracts? The easy answer is bioavailability. In pharmacology, bioavailability is a subcategory of absorption and is the fraction of an administered dose of an unchanged drug that reaches the systemic circulation. By definition, when a medication is administered intravenously, its bioavailability is 100%. However, when a medication is administered via other routes (such as orally), its bioavailability generally decreases, due to incomplete absorption, and may vary from patient to patient. Billions are wasted each year on wellness products due to poor bioavailability.”
Phytofare® patented products are specially formulated to have extremely high bioavailability. In practical terms, this means that Plandaí can deliver more of the vital plant nutrients to the blood plasma where it remains at a therapeutic level for over 24 hours. The Plandaí processing and extraction system is unique and enables us to produce extract that deliver higher levels of bioavailability in humans.
In applying this technology to cannabis, Mr. Cottrell-Duffield added, “Live cannabis leaf is inherently non-psychoactive. It is the process of drying and heating the leaf that metabolizes these acid forms into THC, a chemical that triggers the euphoria sought after by recreational users. The commonly used “super critical extraction” method uses extreme temperatures that causes THC to retain these properties. Plandaí’s process, which uses live leaf and low temperatures to extract the phyto-chemicals, should leave the acid forms of THC intact, resulting in a non-psychoactive extract with full medicinal potential.”
About Plandai Biotechnology, Inc.
Plandai Biotechnology, Inc. (OTC Markets: PLPL) develops highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandai Biotechnology, through its South African subsidiaries, controls every aspect of production, from growing specific raw materials such as green tea on its farms to producing its proprietary Phytofare extract, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. The manufacturing facility has also been engineered for citrus fruits and the recovery of Bioflavonoid and limonoids. Targeted industries for the Company's products include animal husbandry, dietary supplements and diabetes. Plandai Biotechnology is headquartered in London, United Kingdom. For more information, please visit: http://www.plandaibiotech.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical facts included in this press release are forward-looking statements. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Investors should not place any undue reliance on forward-looking statements since they involve known and unknown, uncertainties and other factors which are, in some cases, beyond the Company's control which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to operations, results of operations, growth strategy and liquidity. Such risks, uncertainties and other factors, which could impact the Company and the forward-looking statements contained herein are included in the Company's filings with the OTC Markets. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.